Anticancer Drugs Practice Questions

Q: Bleomycin toxicity is characterized by hyperplasia of which of the following cells?

Type II pneumocytes. **Explanation:** **Bleomycin** is a cytotoxic antibiotic that causes DNA strand scission through free radical generation. Its most significant dose-limiting toxicity is **Pulmonary Fibrosis**. **Why Type II Pneumocytes?** The pathogenesis of Bleomycin-induced lung injury involves damage to the alveolar epithelium. Bleomycin causes oxidative stress and damage to **Type I pneumocytes** (which cover 95% of the alveolar surface). In a compensatory attempt to repair the alveolar basement membrane, **Type II pneumocytes undergo hyperplasia** and hypertrophy. However, they fail to differentiate effectively into Type I cells, leading to fibroblast activation and subsequent interstitial fibrosis. This "Type II pneumocyte hyperplasia" is a hallmark histopathological finding. **Analysis of Incorrect Options:** * **A. Endothelial cells:** While bleomycin can cause initial vascular leakage, it does not typically cause endothelial hyperplasia. * **B. Type I pneumocytes:** These cells are extremely sensitive to injury and are **destroyed** (necrosed) by bleomycin, not increased in number. * **D. Alveolar macrophages:** While macrophages are involved in the inflammatory cytokine cascade (TGF-beta), they do not undergo characteristic hyperplasia in this context. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Chelates ferrous iron ($Fe^{2+}$) to form free radicals. * **Cell Cycle:** Specifically acts on the **G2 phase**. * **Metabolism:** Inactivated by **bleomycin hydrolase**. The lung and skin have low levels of this enzyme, explaining the site-specific toxicities (Pulmonary fibrosis and Skin hyperpigmentation/flagellate dermatitis). * **Monitoring:** Pulmonary Function Tests (PFTs) showing a **decrease in DLCO** (Diffusion capacity) is the earliest sign of toxicity. * **Risk Factor:** High inspired oxygen ($FiO_2$) during surgery can exacerbate bleomycin lung injury.

Q: Which of the following is a monoclonal antibody against PD-L1?

Durvalumab. Explanation: Durvalumab is a human monoclonal antibody that targets Programmed Death-Ligand 1 (PD-L1). In the tumor microenvironment, cancer cells express PD-L1, which binds to PD-1 receptors on T-cells, effectively "switching off" the immune response (immune checkpoint). By inhibiting PD-L1, Durvalumab restores T-cell mediated anti-tumor activity. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma. Analysis of Incorrect Options: * Golimumab (A): A monoclonal antibody against TNF-alpha. It is used in the management of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. * Guselkumab (B): An interleukin inhibitor that targets IL-23. It is specifically indicated for moderate-to-severe plaque psoriasis. * Vedolizumab (D): An integrin antagonist (specifically $\alpha_4\beta_7$ integrin) [1]. It is gut-selective and used in the treatment of Inflammatory Bowel Disease (Crohn’s disease and Ulcerative Colitis) [1]. High-Yield NEET-PG Pearls: * PD-1 Inhibitors: Nivolumab, Pembrolizumab, and Cemiplimab (Target the receptor on T-cells). * PD-L1 Inhibitors: Atezolizumab, Avelumab, and Durvalumab (Mnemonic: "AAD" targets the Ligand on tumor cells). * CTLA-4 Inhibitor: Ipilimumab (another major immune checkpoint inhibitor). * Suffix Tip: Monoclonal antibodies ending in "-umab" are fully human, reducing the risk of infusion reactions compared to chimeric ("-ximab") antibodies.

Q: What is the standard chemotherapy regimen for metastatic testicular carcinoma?

Bleomycin, Etoposide, Cisplatin. **Explanation:** The standard of care for metastatic germ cell tumors, including testicular carcinoma, is the **BEP regimen**. This combination is highly effective, often achieving cure rates exceeding 90% even in advanced stages. **1. Why Option A is Correct:** The BEP regimen consists of: * **B**leomycin (Antitumor antibiotic): Causes DNA strand breaks. * **E**toposide (Topoisomerase II inhibitor): Prevents DNA replication. * **P**latin (**Cisplatin**): An alkylating-like agent that forms DNA cross-links. Cisplatin is the "backbone" of this therapy. The synergy between these drugs targets rapidly dividing germ cells at different phases of the cell cycle. **2. Analysis of Incorrect Options:** * **Option B (VEP):** While Vinblastine was historically used (VBP regimen), it has been largely replaced by Etoposide because Etoposide offers better efficacy and lower neurotoxicity. * **Option C:** This combination is not a standard regimen. Doxorubicin and 5-FU are more commonly associated with breast or GI cancers. * **Option D:** These drugs are used in various protocols (like for ALL or colorectal cancer) but lack the specific efficacy required for testicular germ cell tumors. **3. NEET-PG High-Yield Pearls:** * **Toxicity Profile:** * **Bleomycin:** Pulmonary fibrosis (monitor with DLCO). It is "skin and lung" toxic but **bone marrow sparing**. * **Cisplatin:** Nephrotoxicity (prevent with aggressive hydration/Amifostine) and Ototoxicity. * **Etoposide:** Secondary malignancies (specifically AML). * **Tumor Markers:** Always correlate treatment with Beta-hCG, AFP, and LDH levels. * **Alternative:** If Bleomycin is contraindicated (e.g., pre-existing lung disease), the **VIP regimen** (Etoposide, Ifosfamide, Cisplatin) is used.

Q: All of the following are monoclonal antibodies against CD-20 except?

Brentuximab. **Explanation:** The correct answer is **D. Brentuximab**. **1. Why Brentuximab is the correct answer:** Brentuximab vedotin is an antibody-drug conjugate (ADC) directed against **CD30**, not CD20. It consists of a chimeric IgG1 antibody linked to the microtubule-disrupting agent **Monomethyl Auristatin E (MMAE)**. It is primarily used in the treatment of Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (ALCL), where CD30 is highly expressed. **2. Analysis of Incorrect Options (CD20 Inhibitors):** CD20 is a surface antigen found on B-cells. Monoclonal antibodies against CD20 are used for B-cell malignancies and autoimmune disorders. * **Rituximab (Option A):** The prototype chimeric monoclonal antibody against CD20. It is the backbone of therapy for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). * **Ofatumumab (Option B):** A fully human monoclonal antibody that binds to a different epitope on CD20 than Rituximab. It is used in CLL and Multiple Sclerosis. * **Ocrelizumab (Option C):** A humanized anti-CD20 antibody specifically approved for both Relapsing and Primary Progressive Multiple Sclerosis. **3. High-Yield Clinical Pearls for NEET-PG:** * **Obinutuzumab:** Another important Type II anti-CD20 antibody used in CLL. * **CD20 vs. CD30:** Remember **"20 for B-cells"** (Rituximab) and **"30 for Reed-Sternberg cells"** (Brentuximab). * **Adverse Effect:** Infusion-related reactions are common with anti-CD20 drugs; premedication with antihistamines and acetaminophen is required. * **Brentuximab Side Effect:** Peripheral neuropathy is a significant dose-limiting toxicity due to the MMAE component.

Q: Which of the following conditions is NOT treated with ibrutinib?

Acute myeloid leukemia. **Explanation:** **Ibrutinib** is a first-in-class, potent, irreversible inhibitor of **Bruton’s Tyrosine Kinase (BTK)**. BTK is a critical signaling molecule in the B-cell receptor (BCR) pathway, which is essential for the survival, proliferation, and differentiation of **B-lymphocytes**. 1. **Why Acute Myeloid Leukemia (AML) is the correct answer:** AML is a malignancy of the **myeloid** lineage (granulocytes, monocytes, etc.), not the B-cell lineage. Since AML cells do not typically rely on the BTK signaling pathway for survival, Ibrutinib is ineffective and is not an approved treatment for this condition. 2. **Analysis of Incorrect Options:** * **Mantle Cell Lymphoma (MCL):** Ibrutinib is FDA-approved for patients with MCL who have received at least one prior therapy. * **Chronic Lymphocytic Leukemia (CLL):** It is a mainstay of treatment for CLL (and Small Lymphocytic Lymphoma), including cases with the high-risk 17p deletion. * **Waldenstrom’s Macroglobulinemia (WM):** This is a B-cell neoplasm characterized by excess IgM. Ibrutinib is highly effective here as these cells are dependent on BTK signaling. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Covalent (irreversible) binding to a cysteine residue (Cys-481) in the BTK active site. * **Route:** Administered **orally**. * **Key Side Effects:** * **Atrial Fibrillation:** A classic board-favorite side effect. * **Increased Bleeding Risk:** Patients should be monitored for bruising or hemorrhage (avoid use with warfarin). * **Lymphocytosis:** A transient increase in lymphocyte count is common early in treatment as cells move from lymph nodes into the blood.

Q: Which drug can be used in a patient with CML and a T315i mutation?

Ponatinib. **Explanation:** The **T315I mutation** is known as the "gatekeeper mutation" in Chronic Myeloid Leukemia (CML). It involves a substitution of threonine (T) with isoleucine (I) at position 315 of the BCR-ABL tyrosine kinase enzyme. This specific structural change creates steric hindrance that prevents most Tyrosine Kinase Inhibitors (TKIs) from binding to the ATP-binding pocket. **Why Ponatinib is correct:** **Ponatinib** is a third-generation TKI specifically designed with a carbon-carbon triple bond (ethynyl group) that bypasses the steric bulk created by the isoleucine residue. It is currently the only approved TKI effective against the T315I mutation. **Why other options are incorrect:** * **Imatinib (1st Gen):** The prototype TKI; it is highly effective for wild-type BCR-ABL but is completely ineffective against the T315I mutation. * **Nilotinib & Dasatinib (2nd Gen):** While these are more potent than Imatinib and can overcome many other resistance mutations, they cannot bind to the BCR-ABL protein when the T315I mutation is present. **High-Yield Clinical Pearls for NEET-PG:** 1. **Adverse Effect of Ponatinib:** It is associated with a high risk of **arterial thrombosis** (myocardial infarction, stroke) and hepatotoxicity. 2. **Asciminib:** A newer drug (STAMP inhibitor) that binds to the myristoyl pocket; it is also used for T315I mutations in patients resistant to other therapies. 3. **Dasatinib Side Effect:** Classically associated with **pleural effusion**. 4. **Imatinib Side Effect:** Most common is **periorbital edema** and fluid retention.

Q: All of the following drugs are used in the management of ALL except?

All-trans retinoic acid. **Explanation:** The management of **Acute Lymphoblastic Leukemia (ALL)** involves a multi-drug regimen divided into induction, consolidation, and maintenance phases. **Why All-trans retinoic acid (ATRA) is the correct answer:** ATRA is a differentiating agent specifically used for **Acute Promyelocytic Leukemia (APL)**, which is the **M3 subtype of Acute Myeloid Leukemia (AML)**. It works by binding to the PML-RARα fusion protein (caused by the t(15;17) translocation), inducing the maturation of malignant promyelocytes into mature neutrophils. It has no therapeutic role in the management of lymphoid malignancies like ALL. **Analysis of incorrect options:** * **Methotrexate:** A folate antagonist that inhibits dihydrofolate reductase (DHFR). It is a cornerstone of ALL therapy, used both systemically and intrathecally for CNS prophylaxis. * **Prednisolone:** Glucocorticoids are lympholytic and are essential in the induction phase of ALL treatment to rapidly reduce the blast burden. * **L-Asparaginase:** This enzyme depletes asparagine in the serum. Since leukemic lymphoblasts lack asparagine synthetase, they cannot synthesize asparagine and undergo apoptosis. This drug is highly specific for ALL. **High-Yield Clinical Pearls for NEET-PG:** * **ATRA Side Effect:** Watch for **"Retinoic Acid Syndrome"** (fever, dyspnea, pleural effusion), treated with high-dose dexamethasone. * **L-Asparaginase Side Effects:** Acute pancreatitis, thrombosis (due to decreased Antithrombin III), and hypersensitivity reactions. * **Vincristine:** Another key drug for ALL induction; its dose-limiting toxicity is peripheral neuropathy. * **Maintenance Therapy for ALL:** Usually consists of 6-Mercaptopurine (daily) and Methotrexate (weekly).

Q: Rituximab is used for the treatment of which of the following conditions?

Non-Hodgkin's lymphoma. **Rituximab** is a chimeric monoclonal antibody directed against the **CD20 antigen**, which is primarily expressed on the surface of normal and malignant B-lymphocytes [1].1. **Why Option C is Correct:** Rituximab binds to CD20, triggering B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Since **Non-Hodgkin’s Lymphoma (NHL)**, specifically the diffuse large B-cell subtype and follicular lymphoma, is characterized by malignant B-cell proliferation, Rituximab is a cornerstone of therapy (often as part of the R-CHOP regimen) [1].2. **Why Other Options are Incorrect:** * **A. Rheumatoid Arthritis:** While Rituximab *is* used off-label or for refractory cases of RA, it is primarily classified as an anticancer drug in this context. However, it is not the first-line choice compared to its definitive role in B-cell malignancies. * **B. Crohn’s Disease:** This is typically treated with TNF-α inhibitors (e.g., Infliximab, Adalimumab) or integrin inhibitors (Vedolizumab), not CD20 blockers. * **D. Colorectal Carcinoma:** This solid tumor is treated with drugs targeting VEGF (Bevacizumab) or EGFR (Cetuximab), not B-cell specific markers.**High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Anti-CD20 monoclonal antibody.* **Other Indications:** Chronic Lymphocytic Leukemia (CLL) [1], Wegener’s Granulomatosis (GPA), and Pemphigus Vulgaris.* **Specific Side Effect:** **Infusion-related reactions** (hypotension, bronchospasm) are common; patients are often premedicated with antihistamines and acetaminophen [1].* **Black Box Warning:** Risk of **Progressive Multifocal Leukoencephalopathy (PML)** due to JC virus reactivation and Hepatitis B reactivation.

Q: What is the first-line drug therapy for chronic myeloid leukemia?

Imatinib. ### Explanation **Correct Option: D. Imatinib** Chronic Myeloid Leukemia (CML) is characterized by the **Philadelphia chromosome [t(9;22)]**, which creates the **BCR-ABL fusion gene**. This gene encodes a constitutively active **tyrosine kinase** protein that drives uncontrolled myeloid proliferation. **Imatinib** is a 2-phenylaminopyrimidine derivative that acts as a selective **Tyrosine Kinase Inhibitor (TKI)**. It binds to the ATP-binding site of the BCR-ABL enzyme, inhibiting its activity. Due to its high efficacy in achieving complete cytogenetic remission and its superior safety profile, it is the **first-line (gold standard) therapy** for CML in the chronic phase. **Why other options are incorrect:** * **A. Hydroxycarbamide (Hydroxyurea):** It is a ribonucleotide reductase inhibitor used primarily for rapid cytoreduction (lowering high WBC counts) before starting TKIs. It does not induce cytogenetic remission. * **B. Alpha-interferon:** Previously a mainstay of treatment, it is now rarely used due to significant systemic toxicity (flu-like symptoms, depression) and lower efficacy compared to TKIs. * **C. Busulphan:** An alkylating agent used historically for CML. It is now largely obsolete for this indication except as part of conditioning regimens for bone marrow transplantation due to risks like pulmonary fibrosis and prolonged myelosuppression. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Resistance:** The most common cause of Imatinib resistance is a **point mutation** in the BCR-ABL kinase domain (e.g., **T315I mutation**). * **Second-generation TKIs:** Nilotinib, Dasatinib, and Bosutinib (used if Imatinib fails). * **Third-generation TKI:** **Ponatinib** (effective against the T315I mutation). * **Side Effects of Imatinib:** Periorbital edema (most characteristic), fluid retention, and muscle cramps.

Q: Sorafenib is used in which of the following conditions?

Acute myeloid leukemia (AML). **Explanation:** **Sorafenib** is a multi-kinase inhibitor that targets several serine/threonine and receptor tyrosine kinases. Its primary mechanism involves inhibiting **RAF kinase** (part of the MAPK/ERK pathway), **VEGFR-2/3**, and **PDGFR-β**. Crucially for this question, it also inhibits **FLT3 (Fms-like tyrosine kinase 3)**. 1. **Why AML is correct:** Approximately 30% of patients with **Acute Myeloid Leukemia (AML)** possess a **FLT3 mutation** (specifically FLT3-ITD), which is associated with a poor prognosis. Sorafenib acts as a first-generation FLT3 inhibitor. While newer agents like Midostaurin and Gilteritinib are now more specific, Sorafenib remains a clinically recognized treatment option for FLT3-positive AML. 2. **Why other options are incorrect:** * **Multiple Myeloma:** Primarily treated with proteasome inhibitors (Bortezomib), IMiDs (Thalidomide/Lenalidomide), and monoclonal antibodies (Daratumumab). * **CLL:** Managed with BTK inhibitors (Ibrutinib), BCL-2 inhibitors (Venetoclax), or CD20 antibodies (Rituximab). * **ALL:** Treatment involves intensive chemotherapy (Vincristine, Asparaginase) and TKI like Imatinib only if Philadelphia chromosome-positive ($Ph+$). **High-Yield Clinical Pearls for NEET-PG:** * **FDA-Approved Indications:** Sorafenib is a first-line agent for **Advanced Hepatocellular Carcinoma (HCC)** and **Advanced Renal Cell Carcinoma (RCC)**. It is also used in differentiated Thyroid Carcinoma. * **Key Side Effect:** **Hand-foot skin reaction** (palmar-plantar erythrodysesthesia) is a classic board-exam association for Sorafenib. * **Mechanism Shortcut:** Remember Sorafenib as a "Multi-kinase inhibitor" (RAF + VEGF + FLT3).

Question 1

Bleomycin toxicity is characterized by hyperplasia of which of the following cells?

Accepted Answer

Type II pneumocytes

Answer

Endothelial cells

Answer

Type I pneumocytes

Answer

Alveolar macrophages

Question 2

Which of the following is a monoclonal antibody against PD-L1?

Accepted Answer

Durvalumab

Answer

Golimumab

Answer

Guselkumab

Answer

Vedolizumab

Question 3

What is the standard chemotherapy regimen for metastatic testicular carcinoma?

Accepted Answer

Bleomycin, Etoposide, Cisplatin

Answer

Vinblastine, Etoposide, Cisplatin

Answer

Doxorubicin, 5-Fluorouracil, Mercaptopurine

Answer

Methotrexate, 5-Fluorouracil, Vincristine

Question 4

All of the following are monoclonal antibodies against CD-20 except?

Accepted Answer

Brentuximab

Answer

Rituximab

Answer

Ofatumumab

Answer

Ocrelizumab

Question 5

Which of the following conditions is NOT treated with ibrutinib?

Accepted Answer

Acute myeloid leukemia

Answer

Mantle cell lymphoma

Answer

Chronic lymphocytic leukemia

Answer

Waldenstrom's macroglobulinemia

Question 6

Which drug can be used in a patient with CML and a T315i mutation?

Accepted Answer

Ponatinib

Answer

Imatinib

Answer

Nilotinib

Answer

Dasatinib

Question 7

All of the following drugs are used in the management of ALL except?

Accepted Answer

All-trans retinoic acid

Answer

Methotrexate

Answer

Prednisolone

Answer

L-Asparaginase

Question 8

Rituximab is used for the treatment of which of the following conditions?

Accepted Answer

Non-Hodgkin's lymphoma

Answer

Rheumatoid arthritis

Answer

Crohn's disease

Answer

Colorectal carcinoma

Question 9

What is the first-line drug therapy for chronic myeloid leukemia?

Accepted Answer

Imatinib

Answer

Hydroxycarbamide

Answer

Alpha-interferon

Answer

Busulphan

Question 10

Sorafenib is used in which of the following conditions?

Accepted Answer

Acute myeloid leukemia (AML)

Answer

Multiple myeloma

Answer

Chronic lymphocytic leukemia (CLL)

Answer

Acute lymphoblastic leukemia (ALL)

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?